CorMedix (CRMD) Cash from Financing Activities (2012 - 2025)

CorMedix has reported Cash from Financing Activities for 13 years, with the latest figure at -$1.4 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 112.52% year-over-year to -$1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $238.5 million (up 806.01% YoY) and the FY2025 annual result came in at $238.5 million, up 806.01% from the prior year.
• Cash from Financing Activities eased to -$1.4 million in Q4 2025 per CRMD's latest filing, from $150.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $150.5 million in Q3 2025 and troughed at -$1.4 million in Q4 2025.
• A 5-year average of $21.1 million and a median of $6.1 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 9710.09% in 2023, then slumped 112.52% in 2025.
• Over 5 years, Cash from Financing Activities stood at $176992.0 in 2021, then jumped by 3315.74% to $6.0 million in 2022, then tumbled by 92.26% to $467650.0 in 2023, then surged by 2313.18% to $11.3 million in 2024, then sank by 112.52% to -$1.4 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.4 million, $150.5 million, and $83.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.